Document is current
Any future updates will be listed below
-
Authors
,
Mankor, Joanne M.
Paats, Marthe S.
Groenendijk, Floris H.
Roepman, Paul
Dinjens, Winand N. M.
Dubbink, Hendrikus J.
Sleijfer, Stefan
Cuppen, Edwin
Lolkema, Martijn P. J. K.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (HMF2017-8225, HMF2017-8225, HMF2017-8225, HMF2017-8225, HMF2017-8225, HMF2017-8225)
Clinical studies and WGS analyses were financially supported by Hartwig Foundation and Barcode for Life.
- License Information
-
More Information
Article History
Received: 19 July 2019
Revised: 10 January 2020
Accepted: 4 February 2020
First Online: 25 February 2020
Ethics approval and consent to participate
: This study was conducted to the standards of Good Clinical Practice, in full conformance with the “Declaration of Helsinki” (latest amendment), the Dutch laws and regulations and with the Medical Research Involving Human Subjects Act (WMO) in particular. The study was approved by the local independent ethics committee of the University Medical Centre (UMC) Utrecht (MEC-12-023). All subjects enrolled in this study provided their informed consent to participate.
: Not applicable.
: All data described in this study is freely available from the Hartwig Medical Foundation for academic research within the constraints of the consent given by the patients. Standardised procedures and request forms can be found at . All bioinformatic analysis tools and scripts used are available at .
: M.P.J.K.L. has advisory board memberships for Pfizer, Bayer, Roche, JnJ and received research grants from Astellas, JnJ, Sanofi and MSD. H.J.D. is an advisory board member for AstraZeneca. The other authors declare no competing interests.
: Clinical studies and WGS analyses were financially supported by Hartwig Foundation and Barcode for Life. Implementation of the data portal was supported by a grant from KWF Kankerbestrijding (HMF2017-8225, GENONCO).
